Incyte Corp - INCY STOCK NEWS

Incyte (INCY) has announced its participation in two major healthcare investor conferences in March 2025. The company will present at the Cowen 45th Annual Health Care Conference on Monday, March 3, at 11:10 am EST, and at the Leerink Partners 2025 Global Healthcare Conference on Tuesday, March 11, at 9:20 am EST.

Both presentations will be accessible through live webcasts on Investor.Incyte.com and will remain available for replay for 30 days following the events.

Incyte (INCY) reported strong financial results for Q4 and full-year 2024, with total revenues reaching $1.2B (+16% Y/Y) in Q4 and $4.2B (+15% Y/Y) for FY2024. Key revenue drivers included Jakafi, with net revenues of $773M (+11% Y/Y) in Q4 and $2.8B (+8% Y/Y) for FY2024, and Opzelura, with net revenues of $162M (+48% Y/Y) in Q4 and $508M (+50% Y/Y) for FY2024.

The company provided 2025 guidance for Jakafi ($2,925-$2,975M) and Opzelura ($630-$670M). 2025 is expected to be a transformative year with four new product launches, four pivotal study readouts, at least three Phase 3 study initiations, and seven proof of concept study readouts. A key development includes ruxolitinib extended-release meeting FDA bioequivalence criteria, with submission planned by year-end 2025.

Incyte (INCY) has announced the granting of restricted stock unit awards (RSUs) to 24 new employees, totaling 16,301 shares of common stock. These grants were made under the Company's 2024 Inducement Stock Incentive Plan, with both grant date and vesting commencement date set for February 3, 2025. The compensation committee approved these awards as inducement for new employees joining the company, in compliance with Nasdaq Listing Rule 5635(c)(4).

The RSUs will vest over four years, with 25% of the shares vesting annually on each anniversary of the vesting commencement date, contingent upon continued employment with the company.

Incyte (Nasdaq:INCY) has announced its schedule for the fourth quarter and year-end 2024 financial results conference call and webcast. The event is set for 8:00 a.m. ET on Monday, February 10, 2025. The related press release will be issued at 7:00 a.m. ET on the same day.

The call will be accessible via domestic dial-in at 877-407-3042 and international dial-in at 201-389-0864, using the conference ID number 13751174. For those unable to attend, a replay will be available for thirty days. The U.S. replay dial-in number is 877-660-6853 and the international replay dial-in number is 201-612-7415, also using the conference ID number 13751174. Additionally, a live webcast with slides will be accessible at Investor.Incyte.com and available for replay for ninety days.

Incyte and Syndax Pharmaceuticals announced FDA approval of Niktimvo (axatilimab-csfr) in 9 mg and 22 mg vial sizes, with U.S. launch expected in early February. Niktimvo is the first FDA-approved treatment targeting CSF-1R for chronic graft-versus-host disease (GVHD) in patients who failed at least two prior systemic therapies.

The approval was based on the AGAVE-201 trial results, where 75% of patients receiving 0.3 mg/kg every two weeks achieved response at six months. The approved dose is 0.3 mg/kg (max 35 mg) via intravenous infusion every two weeks for patients weighing at least 40 kg.

Notable adverse reactions occurred in 44% of patients, with 10% discontinuing treatment. The most common side effects included increased AST, infections, and decreased phosphate levels. The treatment has been added to NCCN Guidelines as a category 2A recommendation.

Incyte (NASDAQ:INCY) presented its growth strategy and 2025 milestones at the 43rd Annual J.P. Morgan Healthcare Conference. The company anticipates a transformational 2025 with four potential product launches, four pivotal trial readouts, seven proof of concept data readouts, and at least three Phase 3 study initiations.

Key highlights include the launch of Niktimvo™ (axatilimab-csfr) for chronic graft-versus-host disease, developments in tafasitamab following positive Phase 3 inMIND trial results for follicular lymphoma, povorcitinib's potential in hidradenitis suppurativa, mCALR-targeting molecule for myelofibrosis and essential thrombocythemia, and their CDK2 inhibitor for ovarian cancer treatment.

The company projects more than 10 high-impact launches across its portfolio by 2030, positioning itself for long-term growth.

Incyte (INCY) has announced the granting of restricted stock unit awards (RSUs) to 14 new employees, totaling 9,502 shares of company common stock. These grants were made under the company's 2024 Inducement Stock Incentive Plan, with both grant date and vesting commencement date set for January 2, 2025. The awards were approved by the compensation committee of Incyte's board of directors as an inducement for new employees joining the company, in compliance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest in four equal annual installments of 25% each, contingent upon continued employment with the company.

Incyte (INCY) has announced equity inducement awards for its new Executive Vice President and Head of U.S. Oncology, Mohamed Issa. The awards, approved by the company's compensation committee under Nasdaq Listing Rule 5635(c)(4), include two separate RSU grants:

1. An initial award of 48,671 restricted stock units (RSUs) with a grant and vesting date of January 6, 2025

2. A subsequent award of 27,812 RSUs to be granted on June 30, 2025

Both awards will vest over four years, with 25% vesting annually, contingent on Dr. Issa's continued employment with the company.

Incyte (Nasdaq: INCY) announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference.

The event will be held on Monday, January 13, 2025, at 10:30 am (PST). The presentation will be webcast live and accessible through Investor.Incyte.com. A replay of the webcast will be available for 30 days.